Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,602 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Investigating age and ethnicity as novel high-risk phenotypes in mucinous ovarian cancer: retrospective study in a multi-ethnic population.
Olaoye T, - A, Boyle W, Williams A, Ganesan R, Subba K, Goyal A, Leung E, Chowdhary R, Pascoe J, Williams S, Yap J, Balega J, Kumar S, Singh K, Sundar SS. Olaoye T, et al. Among authors: williams a, williams s. Int J Gynecol Cancer. 2024 Sep 2;34(9):1399-1407. doi: 10.1136/ijgc-2024-005332. Int J Gynecol Cancer. 2024. PMID: 38862154 Free PMC article.
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom.
Sundar S, Manchanda R, Gourley C, George A, Wallace A, Balega J, Williams S, Wallis Y, Edmondson R, Nicum S, Frost J, Attygalle A, Fotopoulou C, Bowen R, Bell D, Gajjar K, Ramsay B, Wood NJ, Ghaem-Maghami S, Miles T, Ganesan R. Sundar S, et al. Among authors: williams s. Int J Gynecol Cancer. 2021 Feb;31(2):272-278. doi: 10.1136/ijgc-2020-002112. Epub 2021 Jan 19. Int J Gynecol Cancer. 2021. PMID: 33468564 Review.
British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic.
Taylor A, Sundar SS, Bowen R, Clayton R, Coleridge S, Fotopoulou C, Ghaem-Maghami S, Ledermann J, Manchanda R, Maxwell H, Michael A, Miles T, Nicum S, Nordin A, Ramsay B, Rundle S, Williams S, Wood NJ, Yiannakis D, Morrison J. Taylor A, et al. Among authors: williams s. Int J Gynecol Cancer. 2022 Jan;32(1):9-14. doi: 10.1136/ijgc-2021-002942. Epub 2021 Nov 18. Int J Gynecol Cancer. 2022. PMID: 34795019
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF; HGSC CRS Collaborative Network (Supplementary 1); Singh N. Cohen PA, et al. Gynecol Oncol. 2019 Aug;154(2):441-448. doi: 10.1016/j.ygyno.2019.04.679. Epub 2019 May 19. Gynecol Oncol. 2019. PMID: 31118141 Free article. Review.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, Gallardo-Rincon D, Blagden S, Brenton J, Perren TJ, Sundar S, Lord R, Dark G, Hall M, Banerjee S, Glasspool RM, Hanna CL, Williams S, Scatchard KM, Nam H, Essapen S, Parkinson C, McAvan L, Swart AM, Popoola B, Schiavone F, Badrock J, Fananapazir F, Cook AD, Parmar M, Kaplan R, Ledermann JA. Clamp AR, et al. Among authors: williams s. Lancet Oncol. 2022 Jul;23(7):919-930. doi: 10.1016/S1470-2045(22)00283-2. Epub 2022 Jun 9. Lancet Oncol. 2022. PMID: 35690073 Free PMC article. Clinical Trial.
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Morgan RD, McNeish IA, Cook AD, James EC, Lord R, Dark G, Glasspool RM, Krell J, Parkinson C, Poole CJ, Hall M, Gallardo-Rincón D, Lockley M, Essapen S, Summers J, Anand A, Zachariah A, Williams S, Jones R, Scatchard K, Walther A, Kim JW, Sundar S, Jayson GC, Ledermann JA, Clamp AR. Morgan RD, et al. Among authors: williams s. Lancet Oncol. 2021 Feb;22(2):277-288. doi: 10.1016/S1470-2045(20)30591-X. Epub 2020 Dec 22. Lancet Oncol. 2021. PMID: 33357510 Free PMC article. Clinical Trial.
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study.
Lee LYW, Starkey T, Ionescu MC, Little M, Tilby M, Tripathy AR, Mckenzie HS, Al-Hajji Y, Barnard M, Benny L, Burnett A, Cattell EL, Charman J, Clark JJ, Khan S, Ghafoor Q, Illsley G, Harper-Wynne C, Hattersley RJ, Lee AJX, Leonard PC, Liu JKH; NCRI Consumer Forum; Pang M, Pascoe JS, Platt JR, Potter VA, Randle A, Rigg AS, Robinson TM, Roques TW, Roux RL, Rozmanowski S, Tuthill MH, Watts I, Williams S, Iveson T, Lee SM, Middleton G, Middleton M, Protheroe A, Fittall MW, Fowler T, Johnson P. Lee LYW, et al. Among authors: williams s. Lancet Oncol. 2022 Jun;23(6):748-757. doi: 10.1016/S1470-2045(22)00202-9. Epub 2022 May 23. Lancet Oncol. 2022. PMID: 35617989 Free PMC article.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, Hook J, Coyle C, Blagden S, Brenton JD, Naik R, Perren T, Sundar S, Cook AD, Gopalakrishnan GS, Gabra H, Lord R, Dark G, Earl HM, Hall M, Banerjee S, Glasspool RM, Jones R, Williams S, Swart AM, Stenning S, Parmar M, Kaplan R, Ledermann JA. Clamp AR, et al. Among authors: williams s. Lancet. 2019 Dec 7;394(10214):2084-2095. doi: 10.1016/S0140-6736(19)32259-7. Epub 2019 Nov 29. Lancet. 2019. PMID: 31791688 Free PMC article. Clinical Trial.
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study.
Lee LYW, Ionescu MC, Starkey T, Little M, Tilby M, Tripathy AR, Mckenzie HS, Al-Hajji Y, Appanna N, Barnard M, Benny L, Burnett A, Cattell EL, Clark JJ, Khan S, Ghafoor Q, Panneerselvam H, Illsley G, Harper-Wynne C, Hattersley RJ, Lee AJ, Lomas O, Liu JK, McCauley A, Pang M, Pascoe JS, Platt JR, Patel G, Patel V, Potter VA, Randle A, Rigg AS, Robinson TM, Roques TW, Roux RL, Rozmanowski S, Taylor H, Tuthill MH, Watts I, Williams S, Beggs A, Iveson T, Lee SM, Middleton G, Middleton M, Protheroe A, Fittall MW, Fowler T, Johnson P; UK Coronavirus Cancer Programme. Lee LYW, et al. Among authors: williams s. Eur J Cancer. 2022 Nov;175:1-10. doi: 10.1016/j.ejca.2022.06.038. Epub 2022 Jul 13. Eur J Cancer. 2022. PMID: 36084618 Free PMC article.
Utility of COVID-19 Screening in Cancer Patients.
Lee LYW, Hill T, Topping O, Tilby M, Baker M, Greig J, Isherwood L, Miller R, Petrenko Y, Desai R, Field A, Kennedy B, Khan S, Kountourou A, Ndlovu S, Starkey T, Storey F, Turner L, Vaughan-Williams W, Moyler S, Preston H, Latty B, Walker S, Henderson DR, Thompson J, Jones N, Ghafoor Q, Pascoe J, Williams S, Middleton G; UK Birmingham Chemotherapy Cancer COVID-19 Project. Lee LYW, et al. Among authors: williams s. Cancer Cell. 2020 Sep 14;38(3):306-307. doi: 10.1016/j.ccell.2020.07.009. Epub 2020 Jul 24. Cancer Cell. 2020. PMID: 32730750 Free PMC article. No abstract available.
11,602 results
You have reached the last available page of results. Please see the User Guide for more information.